| (Values in U.S. Thousands) | Apr, 2025 | Jan, 2025 | Oct, 2024 | Jul, 2024 | Apr, 2024 |
| Sales | 6,400 | 7,330 | 6,210 | 7,530 | 8,020 |
| Sales Growth | -12.69% | +18.04% | -17.53% | -6.11% | -6.20% |
| Net Income | -2,790 | -1,540 | -3,380 | -13,380 | -3,020 |
| Net Income Growth | -81.17% | +54.44% | +74.74% | -343.05% | +1.31% |
Enzo Biochem Inc (ENZB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Fiscal Year End Date: 07/31